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OBJECTIVE
Identifying maturity-onset diabetes of the young (MODY) in pediatric populations
close to diabetes diagnosis is difﬁcult. Misdiagnosis and unnecessary insulin
treatment are common. We aimed to identify the discriminatory clinical features
at diabetes diagnosis of patientswith glucokinase (GCK), hepatocyte nuclear factor-
1A (HNF1A), and HNF4A MODY in the pediatric population.
RESEARCH DESIGN AND METHODS
Swedish patients (n5 3,933) aged1–18 years, diagnosedwith diabetesMay 2005 to
December 2010 were recruited from the national consecutive prospective cohort
Better Diabetes Diagnosis. Clinical data, islet autoantibodies (GAD antibody,
insulinoma antigen-2A, zinc transporter 8A, and IAA), HLA type, and C-peptide
were collected at diagnosis. MODY was identiﬁed by sequencing GCK, HNF1A, and
HNF4A, either through routine clinical or research testing.
RESULTS
The minimal prevalence of MODY was 1.2%. Discriminatory factors for MODY at
diagnosis included four islet autoantibody negativity (100 vs. 11% not-known
MODY; P5 23 10244), HbA1c (7.0 vs. 10.7% [53 vs. 93 mmol/mol]; P5 13 10
220),
plasma glucose (11.7 vs. 26.7 mmol/L; P5 33 10219), parental diabetes (63 vs. 12%;
P 5 1 3 10215), and diabetic ketoacidosis (0 vs. 15%; P 5 0.001). Testing
303 autoantibody-negative patients identiﬁed 46 patients with MODY (detection
rate 15%). Limiting testing to the 73 islet autoantibody-negative patients with
HbA1c <7.5% (58mmol/mol) at diagnosis identiﬁed 36 out of 46 (78%) patients with
MODY (detection rate 49%). On follow-up, the 46 patientswithMODYhad excellent
glycemic control, with an HbA1c of 6.4% (47 mmol/mol), with 42 out of 46 (91%)
patients not on insulin treatment.
CONCLUSIONS
At diagnosis of pediatric diabetes, absence of all islet autoantibodies and modest
hyperglycemia (HbA1c <7.5% [58 mmol/mol]) should result in testing for GCK,
HNF1A, and HNF4A MODY. Testing all 12% patients negative for four islet
autoantibodies is an effective strategy for not missing MODY but will result
in a lower detection rate. Identifying MODY results in excellent long-term glycemic
control without insulin.
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Maturity-onset diabetes of the young
(MODY) is a monogenic, dominantly in-
heriteddiabetesthat is typicallydiagnosed
young but is not insulin dependent. Rec-
ognizingMODY is important, as treatment
and management is different from type
1 and type2diabetes. Diabetes in children
is predominantly type1diabetes, but type
2 diabetes and MODY also occur (1,2).
MODY accounts for 1–4% of pediatric
diabetes (1,3–7), but misdiagnosis results
in many young people being treated un-
necessarily with insulin (1,4), with many
years’ delay from initial diabetes diagnosis
to correct genetic diagnosis (8).
The most common subtypes of MODY
areglucokinase(GCK)MODY,whichneeds
no treatment, and hepatocyte nuclear
factor-1a (HNF1A) MODY and HNF4A
MODY, which are both optimally treated
with low-dose sulphonylureaswhenphar-
maceutical therapy is needed (2,9).
Identifying MODY in pediatric popu-
lations with diabetes is diagnostically
difﬁcult, as no single criterion or combi-
nation of commonly used clinical criteria
can adequately separate them from
type 1 and type 2 diabetes (1,2,10,11).
This is particularly true close to diagnosis,
when those with type 1 diabetes con-
tinue to produce endogenous insulin.
Increasing obesity in all children (12)
can also make differential diagnosis
from type 2 diabetes challenging (13).
Islet autoantibodies can be useful in
identifying non–type 1 diabetes and are
rarely detected in MODY, being present
in only 1% of cases, similar to the healthy
population (14). In contrast, islet auto-
antibodies are detected in ;90% of
childrenwith type 1diabetes at diagnosis
(15,16).Despite this, useof islet autoanti-
bodies is not universally advocated, and
comprehensive islet autoantibody test-
ing of all four subtypesdGAD antibody
(GADA), insulinoma antigen-2A (IA-2A),
zinc transporter 8A (ZnT8A), and insulin
autoantibody (IAA)dis not routinelyper-
formed in clinical care.
A correct diagnosis of MODY in children
and adolescents leads to improved treat-
ment with the avoidance of insulin, no
deterioration in HbA1c (17,18), and cost
savings (19).Making the genetic diagnosis
as close as possible to the diabetes di-
agnosis will reduce delays in starting
recommended treatment. Approaches
to the recognition of MODY are currently
predominantly based on clinical features
at follow-up rather than at diagnosis (20).
The aim of our study was to identify the
discriminatory clinical features of the
most common types of MODY at diag-
nosis of diabetes in a pediatric national
cohort.
RESEARCH DESIGN AND METHODS
Individuals aged between 1 and 18 years
with a new diagnosis of diabetes were
recruited from the national consecutive
prospective cohort Better Diabetes Di-
agnosis (BDD)study, involving42hospital
pediatric clinics in Sweden, from May
2005 to December 2010 (21). A total of
4,574 children and young people be-
tween 1 and 18 years of age were di-
agnosed with diabetes during the study
period, and 3,933 (86%) were recruited
into the study cohort (Fig. 1). Participants
were 45% female (n 5 1,755) and had a
mean age of diagnosis of 10.1 years.
Patients with incidental hyperglycemia
or impaired fasting glucose and not
thought to have diabetes were not in-
cluded in the BDD study.
Clinical Characteristics
Clinical data including symptoms of poly-
uria, polydipsia, and weight loss, family
history of diabetes, samples for plasma
glucose concentration, HbA1c, and islet
autoantibodies againstGADA, IA-2A, ZnT8A,
and insulin, HLA type, and C-peptide
were collected at diagnosis. The routine
laboratory tests, plasma glucose, pH, and
HbA1c were analyzed locally, with results
returned within 24 h and are described
as early investigations (Supplementary
Table 1). Diabetic ketoacidosis (DKA) was
deﬁnedas pH,7.3or serumbicarbonate
,15 mEq/L with a plasma glucose
.11 mmol/L. Blood samples sent to
the reference laboratory for analyses
of all islet autoantibodies (GADA, IA-2A,
ZnT8A, and IAA), HLA genotype, and
random C-peptide are described as de-
layed, as the results were returned to
the clinician within 14 to 90 days
(Supplementary Table 1). Demographic
data, symptoms, physical signs, and
blood analysis at onset were registered
in SWEDIABKIDS, a national incidence
and longitudinal quality control register
for children and adolescents with di-
abetes (22).
Molecular genetic testing was under-
taken to identify the most common causes
ofMODY (GCK,HNF1A, andHNF4A), all of
which need different treatment from
type 1 or type 2 diabetes. The molecular
genetic sequencing of the whole coding
region and critical noncoding regions of
each gene was either performed because
of a clinical request or as a research test at
the diagnostic laboratory at the Royal
Devon and Exeter NHS Foundation Trust
(www.diabetesgenes.org) or at the De-
partment of Clinical Chemistry, Division of
Laboratory Medicine, Ska˚ne University
Hospital. Clinical referrals for genetic
testing were predominantly requested
in autoantibody-negative patients (76
out of 81 [94%]) (Fig. 1).
Of those who were islet autoantibody
negative, there were a total of 386 out of
462 patients who were not tested clin-
ically. To assess if case subjects with
MODY had been missed that would alter
treatment, research sequencing of the
HNF1A, HNF4A, and GCK genes was un-
dertaken in an additional 404 patients
(227 autoantibody negative and 177 au-
toantibody positive). We research tested
all 227 autoantibody-negative patients
in whom there was sufﬁcient DNA for
genetic sequencing. There were 159
islet autoantibody–negative patients
who were not tested on a clinical or
research basis, as there was insufﬁ-
cient DNA available (Fig. 1). We com-
pared the characteristics of the 159 islet
autoantibody–negative patients not re-
search tested with the 227 research-
tested patients (Supplementary Table
2). No variables were signiﬁcant after
correction for multiple testing. Therefore,
the patients research tested were repre-
sentative of the whole group who were
islet autoantibody negative and not tested
clinically.
To provide a random collection of
autoantibody-positive patients, we iden-
tiﬁed 250 consecutive patients. Research
sequencing was performed on the 177 of
these islet autoantibody–positive pa-
tients who had not been tested clinically
for whom we had an adequate quantity
of DNA for genetic testing.We compared
the characteristics of the randomly se-
lected 177 autoantibody-positive pa-
tients who were research tested for
MODY to the 3,294 antibody-positive
patients who were not tested (Supple-
mentary Table 3). No variables except
C-peptide were signiﬁcant after correc-
tion for multiple testing. Therefore, the
patients research tested were represen-
tative of the whole group who were islet
autoantibody positive and not tested
clinically.
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Details of Testing
Autoantibodies
Autoantibodies against GADA, IA-2A, ZnT8A,
and IAA were analyzed in radiobinding
assays (23). The cutoff values used equated
to the level found in only 1% of an age-
matched population (23). GADA and IA-2A
levelswereexpressedasunitspermilliliter
derived from the World Health Organiza-
tion standard 97/550 and were consid-
ered positive if GADA were.35 units/mL
andIA-2Alevels.5units/mL.Theintra-assay
coefﬁcient of variation (CV) for duplicates
was 5% for GADA and 11% for IA-2A.
The radio ligand binding assays for all
three ZnT8 autoantibody (ZnT8A) var-
iants (ZnT8RA, ZnT8WA, and ZnT8QA)
were analyzed (24). Cutoff values for
positiveresultswereZnT8RA$75units/mL,
ZnT8WA$75 units/mL, and ZnT8QA$100
units/mL. The intra-assay CV was 5.5% for
ZnT8RA, 5.3% for ZnT8WA, and 4.9% for
ZnT8QA. IAA was considered positive if it
was.0.8 relative units. The intra-assay CV
in the IAA assay was 6.0% (23).
The laboratory undertaking the autoan-
tibody analyses participates in the biannual
Islet Autoantibody Standardization Program
(http://www.immunologyofdiabetessociety
.com/).
HLA Genotyping
Dried blood spots were used for PCR
ampliﬁcation with sequence-speciﬁc ol-
igonucleotide probes of HLA-DQB1 and
DQA1 alleles using a DELFIA Hybridiza-
tion assay (PerkinElmer, Boston, MA)
(25). The HLA-DQB1* probes deﬁned the
presence of HLA-DQB1*02, 03:02, 03:01,
06:02, 06:03, and 06:04 alleles, and the
HLA-DQA1 probes the DQA1*02:01, 03,
and 05 alleles (25–27).
C-peptide Measurement
Serum C-peptide, from the random non-
fasting blood samples, was measured at
Linkoping University with a time-resolved
ﬂuoroimmunoassay (AutoDELFIA C-peptide
kit; Wallac, Turku, Finland), with a de-
tection level of 0.03 nmol/L (28).
Molecular Genetic Testing for MODY
The coding exons and conserved splice
sites of HNF1A, HNF4A, and GCK were
ampliﬁedbyPCRandsequencedonanABI
3730 (Applied Biosystems, Warrington,
U.K.). Sequences were compared with
the published reference sequences
(NM_000545.6 for HNF1A, NM_175914.4
for HNF4A, and NM_000162.5 for GCK)
using Mutation Surveyor v3.24 (SoftGe-
netics, State College, PA) or ABI SeqScape
Software v2.5 (Applied Biosystems). Var-
iants were classiﬁed according to the
American College of Medical Genetics
and Genomics guidelines (29). MODY
was diagnosed by the identiﬁcation of
heterozygous pathogenic or likely patho-
genic variants.
Statistical Methods
For statistical testing of binary variables,
we used the Fisher exact test, and for
continuous traits, we used unpaired t
tests. Where the continuous traits were
notnormallydistributed,welog-transformed
the variable and indicated this in the
tables legends. All analyses were per-
formed in Stata v14.
Ethical Approval
The Regional Ethics Board at Karolinska
Institute approved the BDD study (Dnrs
2004–826/1, 2006/1082–32, and 2009/
1684–32).
The study is written in linewith STrength-
ening the Reporting of OBservational stud-
ies in Epidemiology guidelines (https://
strobe-statement.org/) for cohort studies.
RESULTS
Eighty-eight percent of Patients
Were Positive for at Least One
Islet Autoantibody
When all four autoantibodies were ana-
lyzed, 88% (3,471out of 3,933) of patients
were positive for at least one islet auto-
antibody. The characteristics of the
autoantibody-positive and autoantibody-
negative patients are provided in Supple-
mentary Table 1. We examined how
Figure 1—Study ﬂow diagram. MODY was only identiﬁed in islet autoantibody-negative patients.
All subjects were tested for GADA, IA-2A, ZnT8A, and IAA islet autoantibodies. Antibody positive
was deﬁned by at least one of these four autoantibodies being positive. The autoantibody results
were fed back to the clinicians soon after diagnosis. The genetic tests are shown in the shaded
boxes. *Genetic tests initiated by the clinician for MODY using routine diagnostic services are
shown as “clinical test.” **Genetic tests performed as part of the study to identify casesmissed by
clinical testing are deﬁned as “research test.”
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testing a lower number of autoantibodies
would change the number of individuals
identiﬁed as autoantibody negative (Table
1). Table 1 shows that each additional
autoantibody tested result in less autoanti-
body-negative patients being identiﬁed,
but with a reducing impact. Therefore,
the number of autoantibody-negative
patients is 49% with GADA testing only,
17% with GADA and IA-2A, 13% with
GADA, IA-2A, and ZnT8A, and 12% with
all four autoantibodies. The detailed break-
down of the distribution of different auto-
antibodies is in Supplementary Fig. 1.
MODY Was Only Identiﬁed in
Autoantibody-Negative Patients
There were no subjects withMODY iden-
tiﬁed in the autoantibody-positive pa-
tients tested either clinically (n 5 5) or
throughresearch testingof consecutively
selected individuals (n 5 177) (Fig. 1).
Clinical Features of Those With
Conﬁrmed MODY
The strongest discriminatory clinical fea-
tures of MODY at diagnosis was being
negative to all four islet autoantibodies
(100 vs. 11% not-known MODY; P 5 2 3
10244). Other key discriminatory features
were: lowerHbA1c, 7.0 versus 10.7% (53 vs.
93 mmol/mol; P 5 1 3 10220), lower
random plasma glucose (mean 11.7 vs.
26.7 mmol/L; P 5 3 3 10219), parental
diabetes (63 vs. 12%;P51310215), and
not having DKA (0 out of 46 vs. 601 out of
3,887; P 5 0.001) (Table 2).
There Was a High Detection Rate of
MODY, 34 out of 76 (45%), in the
Autoantibody-Negative Patients
Tested on Clinician’s Request
Clinical molecular genetic diagnosis of
MODY in these 34 patientswasmade at a
median of 9 (interquartile range 4–21)
months post–clinical diagnosis of diabetes
(Fig. 1). The patients clinically testedwere
more likely to be autoantibody negative,
had lower plasma glucose and HbA1c, and
were more likely to have a parent with
diabetes (Supplementary Table 4).
There was a lower rate of MODY
detection, 12 out of 227 (5%), in the
autoantibody-negative patients who had
genetic testing as part of this research
andwere not referred for genetic testing
by their clinicians (Fig. 1).
The MODY subtypes identiﬁed were:
GCK MODY in 29 (63%), HNF1A MODY in
10 (22%), and HNF4A MODY in 7 (15%)
patients. The distribution of the different
MODY types in the autoantibody-negative
group, not referred for genetic testing by
clinicians and tested on a research basis,
was similar. The speciﬁc gene variants
identiﬁed are shown in Supplementary
Table 5.
Fifteen Percent of Autoantibody-Negative
Patients Have MODY, Resulting in a
Minimal Prevalence of 1.2%
When 303 autoantibody-negative pa-
tients were genetically tested 46 had
MODY (15%). This equates to a minimal
prevalence of 1.2% (46 out of 3,933) (Fig.
1). If we assume the detection rate of
MODY in the 159 autoantibody-negative
patients who were not tested on a re-
search basis was 5% as seen in the
227 patients who were research tested,
we would expect to ﬁnd an additional
8 patients with MODY (Fig. 1). an esti-
mated prevalence of 1.4% (54 out of
3,933) in this pediatric population.
Clinical Feature of MODY in
Autoantibody-Negative Patients
Among the 462 autoantibody-negative
patients, the 46 patients with MODY
had markedly less severe hyperglycemia
than those not known to have MODY.
HbA1c (7.0 vs. 10.2% [53 vs. 88 mmol/
mol]) and mean random plasma glucose
(11.7 vs. 23.7mmol/L)were less severe in
the patients with MODY (Fig. 2 and
Supplementary Fig. 2). They were less
likely to have osmotic symptoms (poly-
uria and polydipsia) and weight loss but
more likely to have a parent with di-
abetes (63 vs. 27%; P 5 4 3 1026)
(Supplementary Table 6). In a multiple
logistic regression model in this autoan-
tibody-negative group of all variables
that were signiﬁcant in univariate anal-
ysis (P, 0.05), only plasma glucose (P5
6 3 1025) and parental history of di-
abetes (P 5 0.02) remained statistically
signiﬁcant discriminators of MODY. The
characteristics of GCK, HNF1A, and HNF4A
MODY compared with patients with not-
known MODY and to each other are
shown in Supplementary Tables 7–9.
Testing Using Previously Suggested Clinical
Criteria for Discriminating MODY
We went on to test how two previously
deﬁned criteria, relating to HbA1c and
family history, altered the detection rate
andthenumberofpatients identiﬁedinthe
303 autoantibody-negativepatients genet-
ically tested for MODY (Supplementary
Table 10). We used HbA1c rather than
plasma glucose even though the latter
was slightly more discriminatory, as it is
used in previous clinical criteria and less
variable than glucose.
If testing was limited to the 73 pa-
tients who, in addition to being auto-
antibody negative, also had an HbA1c
below thepreviously deﬁnedupper limit
of HbA1c 7.5% (58 mmol/mol) for the
diagnosis of GCK MODY (30), this im-
proved the detection rate to 49%
(36 out of 73) and identiﬁed 78%
(36 out of 46) of patients with MODY.
These criteria, as expected, were excel-
lent for detecting GCK MODY (29 out of
29 patients) but also detected 41%
Table 1—The number of patients positive for autoantibodies varies with the number of autoantibodies tested at diagnosis in
BDD, a national cohort of pediatric diabetes
Number of autoantibodies
tested Autoantibody positive to
N positive (%) (out of
3,933)
N (%) of people who tested negative with this
testing of antibody combination
One antibody GADA 2,081 (53) 1,852 (47)
IA-2A 2,718 (69) 1,215 (31)
Two antibodies GADA and/or IA-2A 3,263 (83) 670 (17)
Three antibodies GADA and/or IA-2A and /or ZnT8A 3,428 (87) 505 (13)
Four antibodies GADA and/or IA-2A and/or ZnT8A and/
or IAA
3,471 (88) 462 (12)
Combinations of commonly tested autoantibodies, illustrating number and percentage of individuals positive to at least one autoantibody and
percentage of patients antibody negative depending on which autoantibodies were tested.
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(7 out of 17) of patients with HNF1A and
HNF4A MODY.
A dominant family history has been a
deﬁning feature of MODY (9). If testing
was limited to patients who were auto-
antibody negative with a parental family
history, this would result in testing
96 people with a detection rate of 30%
(29 out of 96), with 63% (29 out of 46) of
case subjects with MODY detected, with
similar proportions in GCK (18 out of 29)
and HNF1A/4A (11 out of 17) MODY.
If those with HbA1c ,7.5% (58
mmol/mol) or an affected parent were
tested (n5 131), then the detection rate
was 33% (44 out of 131), with 44 out of
46 (96%) of case subjects with MODY
detected.
Therefore, both glycemia at diagnosis
and family history have a role in select-
ing which autoantibody-negative pa-
tients to test, but if selecting on a
single clinical criteria, only then would
HbA1c ,7.5% (58 mmol/mol) be both
more sensitive and more speciﬁc than
family history.
Patients Identiﬁed With a Genetic
Diagnosis of MODY Had an
Excellent Outcome
At a mean of 5.9 years after initial
diabetes diagnosis, excellent glycemic
control was achieved in all individuals
with a genetic diagnosis of MODY with
mean (SD) HbA1c 6.4 (1.0)% (47 [8]
mmol/mol). A total of 42 out of
46 (91%) patients were not on insulin
and were on recommended treatment:
no treatment for GCK MODY (29 out of
29; 100%) and diet or sulphonylurea for
HNF1A MODY (9 out of 10; 90%) and
HNF4AMODY (4out of 7; 57%). A total of
14 out of 18 patients, started on insulin
at initial diabetes diagnosis, had discon-
tinued insulin treatment following a
positive genetic test (Supplementary
Table 11).
Table 2—Clinical features and investigation results of MODY (HNF1A, HNF4A, and GCK) and patients not-known to have MODY
Phenotype
HNF1A/HNF4A/GCK MODY
(n 5 46)
Not-known MODY
(n 5 3,887)^
N Mean (SD) or % (N) N Mean (SD) or % (N) P
Clinical features
N 46 3,887
Sex (% female) 46 54 (25) 3,887 45 (1,730) 0.23
Age at diagnosis (years) 46 12.1 (4.4) 3,887 10.1 (4.4) 3 3 1023
Parental diabetes (%) 46 63 (29) 3,887 12 (471) 1 3 10215
Polyuria (%) 38 34 (13) 3,570 95 (3,378) 2 3 10222
Polydipsia (%) 38 34 (13) 3,559 94 (3,350) 2 3 10221
Weight loss (%) 38 16 (6) 3,449 76 (2,619) 1 3 10214
BMI (SD score) 37 0.54 (1.2) 3,341 20.36 (1.6) 7 3 1024
Acanthosis nigricans (%) 37 0 (0) 3,453 100 (44) 1
Investigations, early*
Plasma glucose (mmol/L) 41 11.7 (4.1) 3,528 26.7 (9.0) 3 3 10219
HbA1c (%) 46 7.0 (3.7) 3,495 10.7 (4.5) 1 3 10
220
DKA (%) 46 0 (0) 3,887 15 (601) 0.001
Investigations, delayed†
Four autoantibody negative (%) 46 100 (46) 3,887 11 (416) 2 3 10244
High-risk HLA (%) 46 20 (9) 3,830 70 (2,684) 3 3 10212
C-peptide (nmol/mol) 41 0.99 (0.63) 3,555 0.34 (0.43) 1 3 10214
C-peptide ,0.2 (nmol/mol) 41 2 (1) 3,555 40 (1,433) 4 3 1028
Plasmaglucose andC-peptide results basedon log10 transformation.^ Not-knownMODYconsists ofn53,471autoantibodypositive (182MODY tested)
and 416 autoantibody negative (257 MODY tested). *Early local testing with results 0–24 h. †Testing at reference laboratories, where results were
delayed (14–90 days).
Figure 2—Patients with MODY had lower HbA1c at diagnosis than those not known to have MODY.
HbA1c in patients with known MODY (both GCK and HNF1A/HNF4A) and those without known
MODY (autoantibody negative and autoantibody positive). Data shown as a box and whisker plot:
the topandbottomendsof theboxare theupperand lowerquartiles, respectively, and themedian
is marked as the horizontal line inside the box. The vertical lines indicate the maximum and
minimum values excluding extreme outliers, shown as dots. HbA1c of 7.5% (58 mmol/mol) cutoff
for GCK MODY (30) shown as a dashed line. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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CONCLUSIONS
This is the ﬁrst large prospective national
study to examine all clinical features at
diagnosis of diabetes. Our study provides
clear support for identifying pediatric
patients for MODY testing by excluding
type1diabetes throughhigh-quality, com-
prehensive autoantibody testing using
four autoantibodies. In the autoanti-
body-negative patients, the most discrim-
inatory clinical features are low glycemia
(plasma glucose or HbA1c) and family
history. Our study suggests that test-
ing autoantibody-negative patients with
HbA1c,7.5% (,58 mmol/mol) will iden-
tify .75% of GCK, HNF1A, and HNF4A
MODY with a detection rate of ;50%.
The minimal incidence of MODY in
patients aged 1–18 years identiﬁed in
this Swedish cohort was 1.2%, and the
estimated prevalence, if all autoantibody-
negative patients had been tested in this
cohort, would be;1.4%. The prevalence
seen in other studies of pediatric diabe-
tes has been reported as follows: Norway
(0.5%) (3), U.S. (1.2%) (1), Italy (1.6% or
6.3% including incidental hyperglycemia)
(5), Australia (1.9%) (6), U.K. (2.5%) (4),
and Poland (3.1–4.2%) (7). However, our
study included a better coverage of the
population (87% of all newly diagnosed
case subjectswithpediatric diabetes), and
our data were collected prospectively, as
opposed to a cross-sectional or selected
cohort. Like the majority of pediatric
studies, the most common etiology is
GCKmutations. If patients with incidental
hyperglycemia or impaired fasting glu-
cose, but not diagnosed with diabetes,
were included, the number of patients
with GCK mutations would have been
increased further (5).
Autoantibody negativity was a key
feature of those identiﬁed with MODY.
This ﬁnding was similar to previous
studies, but within our study, autoanti-
body testing was comprehensive, with
four autoantibodies tested, and also
performed at diagnosis. This approach ef-
ﬁciently leads to more patients with type 1
diabetes being positively identiﬁed and
reduces the number of case subjects need-
ing consideration for MODY testing. The
fact that our cohort was recruited at di-
agnosis means that a low (,200 pmol/L)
C-peptide result was not found in the
majority of patients with autoantibody-
positive type 1 diabetes. C-peptide testing
was used in both U.S. and U.K. studies
(1,4), but both recruited patients who
were usually many years after the initial
diabetes diagnosis.
Our study indicates that very few case
subjects with MODY will be missed if
genetic testing is limited to children who
are negative for all four autoantibod-
ies. As 1% of the normal population is
isletautoantibody positive at the levels
used as cutoffs, then 1% of patients with
MODY can also be expected to have
autoantibodies. However, as MODY is
rare, and type 1 diabetes is common
in pediatric populations with diabetes,
and ;90% of children with type 1 di-
abetes are autoantibody positive close to
diagnosis, the number of patients with
MODY predicted in the autoantibody-
positive patients would be ,0.1%.
Therefore, we consider data from this
and other studies means autoantibody
positivity is a reasonable exclusion for
progressing to genetic testing in a person
with diabetes in the pediatric age range
(14,31).
The breakdown of autoantibody pos-
itivity indicates that there is a clear
beneﬁt for testing three islet autoanti-
bodies (GADA, IA-2A, and ZnT8A). How-
ever, only a few additional patients will
be found to be positive if IAA testing is
also performed at diagnosis. As testing
IAA is technically difﬁcult and only re-
duces the number of patients that are
autoantibody negative from 13% of pe-
diatric diabetes to 12% means it may
not be considered necessary clinically.
In our study, the results of the auto-
antibody tests were returned to all clini-
cians, and this was a major determinant
of which patients the clinicians referred
for genetic testing. This led to a very high
rate of detection of MODY (45%) com-
pared with 27% in reported routine
services (8).
This is the ﬁrst study performed at the
time of diabetes diagnosis. Samples and
data were typically collected at diag-
nosis before insulin was given. The U.S.
SEARCH for Diabetes in Youth (SEARCH)
study includedpatients close todiagnosis
but was typically;8 months post–initial
diabetes presentation (1). Our study
enabled accurate recording of initial
symptoms and acute investigations at
diagnosis of diabetes. The key features
of those withMODYwhomwe identiﬁed
at diabetes diagnosis included lower
HbA1c, lower plasma glucose, and less
osmotic symptoms, which all reﬂect less
severehyperglycemia, and therewereno
patients with MODY who presented in
ketoacidosis.
A key issue is what is the appropriate
level of sensitivity and speciﬁcity of the
threshold set for systematic testing of
patients. The low prevalence of MODY
means thateven featureswithaveryhigh
odds ratio have a low positive predictive
value. Thismakes it hard to identify likely
case subjects, and unduly strict criteria,
while resulting in a high detection rate,
will miss case subjects. With a reduction
in the cost of genetic testing, it may be
the most effective strategy to sequence
all pediatric patients with diabetes who
are negative on testing four autoanti-
bodies, leading to a detection rate of
≅15%. Our results support that prespe-
ciﬁed cutoffs of HbA1c ,7.5% in auto-
antibody-negative patients gives a much
higher detection rate for the person
being tested having MODY (≅50%) but
would miss ≅22% of case subjects with
MODY (mainly HNF1A and HNF4AMODY).
A compromise might be to test all au-
toantibody-negative patients with an
HbA1c ,7.5% or a parent with diabetes;
this approach had a detection rate≅33%
and detected ≅94% of patients with
MODY.
It is interesting that, after receiving the
islet autoantibody results, clinicians chose
to test only 76 out of 462 (16%) of the
autoantibody-negative patients but had
a high detection rate of 34 out of 76 (45%)
in those they did test. The main factors
that inﬂuenced clinician testing were se-
verity of glycemia and family history
(Supplementary Table 12). Ultimately, a
model that integrates all clinical factors
may outperform clinician choice, but at
present, either testing all islet autoanti-
body–negative patients or those with a
predeﬁned HbA1c cutoff of ,7.5% at
diagnosis performs better than clinician
choice with fewer case subjects with
MODY missed.
It is important to detect MODY, as our
results show improved outcome both in
termsof insulin cessation andHbA1c. This
study has prospectively followed up the
long-term impact of a diagnosis ofMODY
from diabetes diagnosis to effect on
clinical outcomes; 42 out of 46 (91%)
patientswere not on insulin at follow-up,
and 14 out of 18 of these had ceased
insulin treatment (which had been
started at initial diabetes diagnosis),
and excellent glycemic control was
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achieved (HbA1cmean [SD] 6.4 [1.0]% [47
(8) mmol/mol]) (Supplementary Table
11). Two out of four of the individuals
still on insulin chose to remain on this
treatment. Stopping insulin can be a
major challenge for some patients,
and this highlights the importance of
identifying the correct genetic diagnosis
as soon as possible (32).
The major strengths of this study are
that it is a large, consecutive series
recruiting 87% of case subjects with
newly diagnosed diabetes in the pediatric
population, allowing assessment of both
clinical features and autoantibodies at
diagnosis.
It is also a strength that all autoanti-
body tests were carried out for the entire
country at a central BDD laboratory at the
Lund University Clinical Research Centre
at Ska˚ne University Hospital. The labo-
ratory is participating in the Islet Auto-
antibody Standardization program and
has very good results. In addition, all
samples are subjected to end point ti-
tration to better deﬁne cutoff levels
compared with a large number of serum
and plasma samples from healthy indi-
viduals. All three isoformsof ZnT8A (R,W,
or Q at position 325) were analyzed to
ensure that children single positive for
any of the three variants were accounted
for (15,23). However, most commonly
clinically used ELISA assays for ZnT8Awill
detect as positive .99% of samples
positive for the three separate isoforms,
as they detect the common R and W
variants. Only pathogenic or likely path-
ogenicvariantshavebeen included in this
study (Supplementary Table 5). The only
likely pathogenic variants are in GCK, and
therefore, further investigations couldbe
performed by testing other family mem-
bers to check for segregation of the
variant with fasting hyperglycemia and
raised HbA1c. Variants of uncertain sig-
niﬁcancewerenot includedbecause they
cannot be used to diagnose MODY.
A weakness of this study is that only
the three most common subtypes of
MODY that can alter treatment were
tested. If a next-generation sequencing
approach is used in children allowing
testing of all case subjects with potential
monogenic subtypes, then there is a
slight increase (;15%) in case subjects
with more monogenic diabetes than the
commonGCK, HNF1A, andHNF4AMODY
alone (4). Thedatapresentedapply to the
Swedish population andwill vary in other
populations, especially when there is a
higher representation of ethnic groups
with a lower prevalence of type 1 di-
abetes and higher prevalence of type 2
diabetes.
In conclusion, at diagnosis of pediatric
diabetes, comprehensive autoantibody
testing and degree of glycemia are key
clinical features ofMODY, allowing differ-
entiation from type 1 diabetes. Establish-
ing negativity to four islet autoantibodies
at diabetes diagnosis in the pediatric
population efﬁciently identiﬁes which
individuals should be considered for
genetic testing. Within the autoantibody-
negative patients, modest hyperglyce-
mia, indicatedby anHbA1c,58mmol/mol
(,7.5%), and family history are further
features that can be used to guide testing.
Identifying patients for genetic testing at
diabetes diagnosis will prevent delays in
the correct molecular genetic diagnosis
of patients. This will lead to improve-
ments in treatment and quality of life and
reductions in treatment and monitoring
costs and should be universally advo-
cated in patients with pediatric diabetes
at diagnosis.
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